503 related articles for article (PubMed ID: 29747823)
1. Gangliosides, α-Synuclein, and Parkinson's Disease.
Ledeen RW; Wu G
Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
[TBL] [Abstract][Full Text] [Related]
2. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
Hadaczek P; Wu G; Sharma N; Ciesielska A; Bankiewicz K; Davidow AL; Lu ZH; Forsayeth J; Ledeen RW
Exp Neurol; 2015 Jan; 263():177-89. PubMed ID: 25448159
[TBL] [Abstract][Full Text] [Related]
3. Neuropathology of α-synuclein in Parkinson's disease.
Choong CJ; Mochizuki H
Neuropathology; 2022 Apr; 42(2):93-103. PubMed ID: 35362115
[TBL] [Abstract][Full Text] [Related]
4. Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse.
Itokazu Y; Fuchigami T; Morgan JC; Yu RK
Mol Ther; 2021 Oct; 29(10):3059-3071. PubMed ID: 34111562
[TBL] [Abstract][Full Text] [Related]
5. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
6. Restoration of Adult Neurogenesis by Intranasal Administration of Gangliosides GD3 and GM1 in The Olfactory Bulb of A53T Alpha-Synuclein-Expressing Parkinson's-Disease Model Mice.
Fuchigami T; Itokazu Y; Morgan JC; Yu RK
Mol Neurobiol; 2023 Jun; 60(6):3329-3344. PubMed ID: 36849668
[TBL] [Abstract][Full Text] [Related]
7. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease.
García-Revilla J; Boza-Serrano A; Jin Y; Vadukul DM; Soldán-Hidalgo J; Camprubí-Ferrer L; García-Cruzado M; Martinsson I; Klementieva O; Ruiz R; Aprile FA; Deierborg T; Venero JL
Acta Neuropathol; 2023 Jul; 146(1):51-75. PubMed ID: 37202527
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
Wu G; Lu ZH; Kulkarni N; Ledeen RW
J Neurosci Res; 2012 Oct; 90(10):1997-2008. PubMed ID: 22714832
[TBL] [Abstract][Full Text] [Related]
10. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
11. Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
Thomzig A; Wagenführ K; Pinder P; Joncic M; Schulz-Schaeffer WJ; Beekes M
Acta Neuropathol; 2021 Jun; 141(6):861-879. PubMed ID: 33895878
[TBL] [Abstract][Full Text] [Related]
12. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
13. Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson's disease.
Guo YL; Duan WJ; Lu DH; Ma XH; Li XX; Li Z; Bi W; Kurihara H; Liu HZ; Li YF; He RR
Acta Pharmacol Sin; 2021 Apr; 42(4):518-528. PubMed ID: 32724177
[TBL] [Abstract][Full Text] [Related]
14. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice.
Cai W; Feng D; Schwarzschild MA; McLean PJ; Chen X
EBioMedicine; 2018 Mar; 29():13-22. PubMed ID: 29433982
[TBL] [Abstract][Full Text] [Related]
15. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Yasuda T; Mochizuki H
Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease.
Suzuki M; Fujikake N; Takeuchi T; Kohyama-Koganeya A; Nakajima K; Hirabayashi Y; Wada K; Nagai Y
Hum Mol Genet; 2015 Dec; 24(23):6675-86. PubMed ID: 26362253
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration.
Wang X; Becker K; Levine N; Zhang M; Lieberman AP; Moore DJ; Ma J
Acta Neuropathol Commun; 2019 Mar; 7(1):41. PubMed ID: 30871620
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts.
Jellinger KA
Mov Disord; 2012 Jan; 27(1):8-30. PubMed ID: 22081500
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease recovery by GM1 oligosaccharide treatment in the B4galnt1
Chiricozzi E; Mauri L; Lunghi G; Di Biase E; Fazzari M; Maggioni M; Valsecchi M; Prioni S; Loberto N; Pomè DY; Ciampa MG; Fato P; Verlengia G; Cattaneo S; Assini R; Wu G; Alselehdar S; Ledeen RW; Sonnino S
Sci Rep; 2019 Dec; 9(1):19330. PubMed ID: 31852959
[TBL] [Abstract][Full Text] [Related]
20. Pathological role of lipid interaction with α-synuclein in Parkinson's disease.
Suzuki M; Sango K; Wada K; Nagai Y
Neurochem Int; 2018 Oct; 119():97-106. PubMed ID: 29305919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
